GLP-1 receptor agonists in primary care: readiness, equity, and the risk of a two-tiered obesity treatment landscape
Therapeutic Advances in Endocrinology and Metabolism
Published online on July 27, 2026
Abstract
Therapeutic Advances in Endocrinology and Metabolism, Volume 17, January-December 2026.
Glucagon-like peptide-1 receptor agonists have transformed obesity pharmacotherapy by producing substantial weight loss and, for semaglutide in patients with established cardiovascular disease, reducing major cardiovascular events. Integrating these ...
Glucagon-like peptide-1 receptor agonists have transformed obesity pharmacotherapy by producing substantial weight loss and, for semaglutide in patients with established cardiovascular disease, reducing major cardiovascular events. Integrating these ...